Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences logo
$89.15 -0.94 (-1.05%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$89.16 +0.01 (+0.01%)
As of 10/23/2026 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
7
Buy
19

Based on 26 Wall Street analysts who have issued ratings for Edwards Lifesciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 7 have given a hold rating, 18 have given a buy rating, and 1 has given a strong buy rating for EW.

Consensus Price Target

$100.27
12.48% Upside
According to the 26 analysts' twelve-month price targets for Edwards Lifesciences, the average price target is $100.27. The highest price target for EW is $115.00, while the lowest price target for EW is $85.00. The average price target represents a forecasted upside of 12.48% from the current price of $89.15.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for EW and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EW Analyst Ratings Over Time

TypeCurrent Forecast
10/25/25 to 10/25/26
1 Month Ago
9/25/25 to 9/25/26
3 Months Ago
7/27/25 to 7/27/26
1 Year Ago
10/25/24 to 10/25/25
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
3 Strong Buy rating(s)
Buy
18 Buy rating(s)
19 Buy rating(s)
18 Buy rating(s)
12 Buy rating(s)
Hold
7 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
9 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$100.27$100.54$99.96$87.06
Forecasted Upside12.48% Upside16.37% Upside20.13% Upside14.33% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

EW Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EW Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Edwards Lifesciences Stock vs. The Competition

TypeEdwards LifesciencesHealthcare CompaniesBroader Market
Consensus Rating Score
2.77
2.32
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside12.48% Upside1,400.11% Upside16.92% Upside
News Sentiment Rating
Positive News

See Recent EW News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/23/2026
Evercore Inc logo
Evercore
3 of 5 stars
Vijay Kumar
Vijay Kumar
4 of 5 stars
Reiterated RatingOutperform
10/15/2026
Weiss Ratings logo
Weiss Ratings
3 of 5 stars
 Reiterated RatingHold (C)
10/15/2026
Robert W. Baird logo
Robert W. Baird
3 of 5 stars
David Rescott
David Rescott
2 of 5 stars
Lower TargetNeutral$94.00 ➝ $90.00+1.91%
10/8/2026Reiterated RatingBuy$90.00 ➝ $110.00+32.73%
10/7/2026UpgradeStrong-Buy
10/5/2026Reiterated RatingBuy$96.00 ➝ $101.00+18.50%
10/2/2026Boost TargetOverweight$100.00 ➝ $105.00+18.89%
9/11/2026Reiterated RatingBuy$110.00+26.88%
8/21/2026 Boost TargetBuy$105.00 ➝ $115.00+30.22%
7/27/2026 Boost TargetBuy$99.00 ➝ $102.00+15.50%
7/24/2026Reiterated RatingOverweight$100.00 ➝ $101.00+20.77%
7/24/2026 Boost TargetMarket Perform$96.00 ➝ $99.00+12.10%
7/24/2026 Boost TargetBuy$102.00 ➝ $105.00+18.89%
7/24/2026 Boost TargetOutperform$100.00 ➝ $103.00+16.63%
7/24/2026 Boost TargetBuy$100.00 ➝ $103.00+16.63%
7/24/2026UpgradeMarket Perform ➝ Outperform$87.00 ➝ $101.00+20.77%
7/21/2026Reiterated RatingBuy$97.00 ➝ $104.00+22.85%
7/16/2026Boost TargetHold$90.00 ➝ $95.00+9.28%
7/15/2026Boost TargetOutperform$100.00 ➝ $105.00+19.31%
7/14/2026 Boost TargetBuy$98.00 ➝ $102.00+15.50%
7/13/2026Boost TargetOutperform$100.00 ➝ $110.00+19.09%
4/24/2026Set TargetHold$87.00 ➝ $85.00+2.10%
4/1/2026 UpgradePeer Perform ➝ Outperform$92.00+14.91%
2/24/2026 Lower TargetBuy$99.00 ➝ $98.00+11.03%
2/11/2026Boost TargetOverweight$96.00 ➝ $100.00+31.67%
1/20/2026Set TargetBuy$105.00 ➝ $110.00+30.35%
10/31/2025 Set Target$92.00+11.54%
10/8/2025DowngradeOutperform ➝ Market Perform
7/25/2025 UpgradeStrong-Buy
7/15/2025Boost TargetEqual Weight$75.00 ➝ $81.00+3.39%
6/2/2025UpgradeHold
12/16/2024 UpgradeNeutral ➝ Buy$82.00 ➝ $90.00+20.97%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:03 PM ET.


Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 23, 2026. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com.

Edwards Lifesciences
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

  • Edwards Lifesciences Co. recently secured FDA approval for its PASCAL Precision system for tricuspid valve repair, a development that positions the company as the only supplier in the U.S. offering both repair and replacement transcatheter options for these valves, significantly expanding its addressable market and competitive moat.
  • The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $0.78 which exceeded the consensus estimate of $0.74, while revenue grew 13.6% year-over-year to $1.74 billion, indicating robust demand for its structural heart disease therapies.
  • Wall Street analysts maintain a positive outlook on the stock, with a consensus rating of Moderate Buy and an average price target of $100.27, which suggests approximately 12% upside potential from the current stock price of $89.15.
  • Edwards Lifesciences Co. maintains a strong balance sheet with a debt-to-equity ratio of only 0.06, providing financial stability and flexibility to invest in research and development without the burden of high leverage, which is particularly attractive in the healthcare sector.
  • The stock has shown consistent momentum, crossing above its 200-day moving average in early October 2026, a technical indicator that often signals the start of a sustained uptrend and increased investor confidence in the company's long-term growth trajectory.

Edwards Lifesciences
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

  • The FDA issued a high-risk early alert regarding a recall of specific lots of the company's Commander M delivery systems due to reports of balloons bursting during procedures, which resulted in one patient death and a serious injury, posing significant regulatory and reputational risks.
  • Insider selling activity has been notable, with multiple executives including VP Daniel J. Lippis and VP Donald E. Bobo Jr. selling thousands of shares in recent months, which can signal a lack of confidence from those with the most intimate knowledge of the company's operations.
  • Several institutional investors have reduced their stakes in the company, with Robeco Institutional Asset Management B.V. decreasing its holdings by 13.0% and Investment House LLC cutting its position by 52.3% in the third quarter, suggesting that large funds are taking profits or reassessing their exposure.
  • The company faces potential margin pressure from tariffs and currency headwinds, as noted by recent analyst commentary, which could erode profitability even if revenue growth continues, particularly given its international operations in Europe and Japan.
  • Short interest in the stock has increased, with shares shorted rising to 9.54 million as of September 30, 2026, indicating that a growing number of traders are betting against the stock's price appreciation, which can create downward pressure on the share price.

EW Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Edwards Lifesciences is $100.27, with a high forecast of $115.00 and a low forecast of $85.00.

26 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 7 hold ratings, 18 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EW shares.

According to analysts, Edwards Lifesciences's stock has a predicted upside of 12.48% based on their 12-month stock forecasts.

Over the previous 90 days, Edwards Lifesciences's stock had 1 upgrade by analysts.

Edwards Lifesciences has been rated by research analysts at Argus, Barclays, BTIG Research, Citigroup, Evercore, JPMorgan Chase & Co., Robert W. Baird, Rothschild & Co Redburn, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like Edwards Lifesciences more than other "healthcare" companies. The consensus rating for Edwards Lifesciences is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how EW compares to other companies.


MarketBeat monitors more than a dozen sources for Edwards Lifesciences analyst ratings, with the most recent rating issued on 10/23/2026.
From Our Partners